|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Boiling Point: | 422.20 °C. @ 760.00 mm Hg (est)
|
| Vapor Pressure: | 0.000000 mmHg @ 25.00 °C. (est) |
| Flash Point: | 408.00 °F. TCC ( 209.10 °C. ) (est)
|
| logP (o/w): | -2.301 (est) |
| Soluble in: |
| | water, 3.943e+004 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LD50 344 mg/kg GASTROINTESTINAL: NAUSEA OR VOMITING Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 353, 1974.
intraperitoneal-mouse LD50 2528 mg/kg National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986
intravenous-mouse LD50 800 mg/kg Drugs in Japan Vol. 6, Pg. 55, 1982.
oral-mouse LD50 > 7000 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
intraperitoneal-rat LD50 3800 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
intravenous-rat LD50 820 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
oral-rat LD50 > 7000 mg/kg Drugs in Japan Vol. -, Pg. 86, 1990.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 4050 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
subcutaneous-rat LD50 > 5500 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for (-)-cyclocytidine hydrochloride usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for (-)-cyclocytidine hydrochloride flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: | View |
| AIDS Citations: | Search |
| Cancer Citations: | Search |
| Toxicology Citations: | Search |
| EPA ACToR: | Toxicology Data |
| EPA Substance Registry Services (SRS): | Registry |
| Laboratory Chemical Safety Summary : | 25050 |
| National Institute of Allergy and Infectious Diseases: | Data |
| WGK Germany: | 2 |
| | (2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol;hydrochloride |
| Chemidplus: | 0010212256 |
| RTECS: | LV2615000 for cas# 10212-25-6 |
References:
| | (2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol;hydrochloride |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 25050 |
| Pubchem (sid): | 134990804 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | ancitabin hydrochlorid | | | ancitabin hydrochloride | | | ancitabine hydrochloride | | 2,2'- | anhydro-1-beta-dextro-arabinofuranosyl cytosine hydrochloride | | 2,2'- | anhydroarabinosylcytosine hydrochloride | | 2,2'- | anhydroaracytidine hydrochloride | | 2,2'- | anhydrocytarabine hydrochloride | | 2,2'- | anhydrocytidine hydrochloride | | | cyclocytidine hydrochloride | | 2,2'-O- | cyclocytidine Hydrochloride | | O-2,2'- | cyclocytidine monohydrochloride | | (2R,3R,3aS,9aR)-2-( | hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol;hydrochloride | | | OCTD hydrochloride |
Articles:
|